All In Biotech

Drug Trial Radar · NCT05046431

Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis

A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Efficacy and Safety of BAT2506 Versus Simponi® in Participants With Active Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Oct 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 704 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

704

Actual

Start

May 6, 2021

Primary completion

Oct 6, 2023

Study completion Oct 6, 2023

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Sep 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, double-blind, randomized, parallel-group study to compare the efficacy,pharmacodynamics (PD), pharmacokinetics (PK), safety, and immunogenicity of BAT2506 versus Simponi® in participants with active PsA. The study will consist of up to 4-week Screening Period, a 52-week Treatment Period, and a 8-week Safety Follow-up Period.

Conditions

  • Psoriatic Arthritis

Interventions

  • BAT2506Drug

    50mg/0.5mL

  • EU SimponiDrug

    50mg/0.5mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ACR20Time frame: Week 8 for EMA or Week 14 for FDA and NMPA

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital Sichuan University

    Chengdu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.